Published in BJU Int on August 13, 2013
Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact? Transl Androl Urol (2016) 0.75
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 6.54
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol (2011) 4.25
Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. BJU Int (2012) 4.01
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol (2013) 3.35
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
The current status of laparoscopic sacrocolpopexy: a review. Eur Urol (2009) 2.85
Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis. Eur Urol (2010) 2.72
FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol (2008) 2.65
Transobturator tape (Uratape): a new minimally-invasive procedure to treat female urinary incontinence. Eur Urol (2004) 2.59
Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. Radiology (2013) 2.47
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet (2008) 2.45
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol (2013) 2.39
Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol (2012) 2.32
Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol (2008) 2.32
Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol (2011) 2.19
Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control--a literature review. Urology (2010) 2.19
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer (2005) 2.15
Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology (2012) 2.13
Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era. Eur Urol (2007) 2.13
Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis (2007) 2.04
Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol (2007) 2.04
Involvement of connexins 43 and 45 in functional mechanism of human detrusor overactivity in neurogenic bladder. Urology (2013) 2.01
Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology (2009) 2.00
Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. Eur Urol (2011) 2.00
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol (2010) 1.82
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A (2009) 1.81
Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol (2012) 1.81
Changing patient perceptions of the side effects of cancer chemotherapy. Cancer (2002) 1.78
Urinary prostate cancer 3 test: toward the age of reason? Urology (2009) 1.64
Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures. Eur Urol (2009) 1.63
Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol (2006) 1.60
Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol (2012) 1.57
Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol (2010) 1.56
Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One (2011) 1.55
The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol (2009) 1.54
Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int (2013) 1.53
Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J Urol (2010) 1.52
Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol (2006) 1.51
A contribution to the improvement of Listeria monocytogenes enumeration in cold-smoked salmon. Int J Food Microbiol (2004) 1.51
Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study. Int J Urol (2013) 1.51
The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. Eur Urol (2011) 1.50
Long-term results of artificial urinary sphincter for women with type III stress urinary incontinence. Eur Urol (2012) 1.50
Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU Int (2014) 1.49
Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol (2011) 1.49
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol (2012) 1.49
Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int (2014) 1.49
Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int (2014) 1.48
Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate (2014) 1.48
Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors? Eur Urol (2010) 1.47
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer (2003) 1.45
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer. Clin Chem (2012) 1.44
Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int (2013) 1.44
Testicular-sparing surgery for bilateral or monorchide testicular tumours: a multicenter study of long-term oncological and functional results. BJU Int (2014) 1.44
Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol (2012) 1.43
Side effects of intradetrusor botulinum toxin injections on ejaculation and fertility in men with spinal cord injury: preliminary findings. BJU Int (2011) 1.43
Long-term functional outcomes after artificial urinary sphincter implantation in women with stress urinary incontinence. BJU Int (2014) 1.42
Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World J Urol (2013) 1.42
Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol (2011) 1.42
Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol (2014) 1.42
Prospective, multidimensional evaluation of sexual disorders in men after laser photovaporization of the prostate. J Sex Med (2013) 1.42
Prostate-sparing cystectomy for bladder cancer: a step toward a dead-end. Urology (2010) 1.41
Quality trials and quality of life in non-small-cell lung cancer. J Clin Oncol (2003) 1.41